Aldrich Melissa B, Velasquez Fred C, Kwon Sunkuk, Azhdarinia Ali, Pinkston Kenneth, Harvey Barrett R, Chan Wenyaw, Rasmussen John C, Ross Russell F, Fife Caroline E, Sevick-Muraca E M
The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX, 77030, USA.
Department of Biostatistics, The School of Public Health, The University of Texas Health Science Center, Houston, TX, 77030, USA.
Arthritis Res Ther. 2017 May 31;19(1):116. doi: 10.1186/s13075-017-1323-z.
Evidence suggests lymphatic function mediates local rheumatoid arthritis (RA) flares. Yet biologics that target the immune system are dosed systemically via the subcutaneous (SC) administration route, thereby inefficiently reaching local lymphatic compartments. Nanotopography has previously been shown to disrupt tight cellular junctions, potentially enhancing local lymphatic delivery and potentially improving overall therapeutic efficacy.
We first characterized nanotopography (SOFUSA™) delivery of an anti-TNF drug, etanercept, by comparing pharmacokinetic profiles to those obtained by conventional SC, intravenous (IV), and intradermal (ID) routes of administration, and assessed uptake of radiolabeled etanercept in draining lymph nodes (LNs) in single dosing studies. We then compared etanercept efficacy in a progressive rat model of collagen-induced arthritis (CIA), administered systemically via SC route of administration; via the regional lymphatics through ID delivery; or through a nanotopography (SOFUSA™) device at 10, 12, and 14 days post CIA induction. Measurements of hind limb swelling and near-infrared fluorescence (NIRF) imaging of afferent lymph pumping function and reflux were conducted on days 11, 13, and 18 post CIA induction and compared to untreated CIA animals. Univariate and multivariate analysis of variance were used to compare the group differences for percentage swelling and lymphatic contractile activity.
Even though all three modes of administration delivered an equal amount of etanercept, SOFUSA™ delivery resulted in increased lymphatic pumping and significantly reduced swelling as compared to untreated, ID, and SC groups. Pharmacokinetic profiles in serum and LN uptake studies showed that using the nanotopography device resulted in the greatest uptake and retention in draining LNs.
Locoregional lymphatic delivery of biologics that target the immune system may have more favorable pharmacodynamics than SC or IV administration. Nanotopography may provide a more efficient method for delivery of anti-TNF drugs to reverse impairment of lymphatic function and reduce swelling associated with RA flares.
有证据表明淋巴功能介导局部类风湿性关节炎(RA)发作。然而,针对免疫系统的生物制剂是通过皮下(SC)给药途径进行全身给药的,因此无法有效地到达局部淋巴区室。纳米拓扑结构先前已被证明可破坏紧密的细胞连接,可能增强局部淋巴输送,并有可能提高整体治疗效果。
我们首先通过将药代动力学特征与通过传统皮下、静脉内(IV)和皮内(ID)给药途径获得的特征进行比较,来表征纳米拓扑结构(SOFUSA™)对抗肿瘤坏死因子(TNF)药物依那西普的递送,并在单次给药研究中评估放射性标记的依那西普在引流淋巴结(LN)中的摄取。然后,我们比较了依那西普在胶原诱导性关节炎(CIA)的渐进性大鼠模型中的疗效,给药途径为:通过SC给药途径全身给药;通过ID递送经区域淋巴管给药;或在CIA诱导后第10、12和14天通过纳米拓扑结构(SOFUSA™)装置给药。在CIA诱导后第11、13和18天对后肢肿胀进行测量,并对传入淋巴泵功能和反流进行近红外荧光(NIRF)成像,并与未治疗的CIA动物进行比较。使用单因素和多因素方差分析来比较肿胀百分比和淋巴收缩活性的组间差异。
尽管所有三种给药方式输送的依那西普量相等,但与未治疗组、ID组和SC组相比,SOFUSA™递送导致淋巴泵功能增强且肿胀明显减轻。血清药代动力学特征和LN摄取研究表明,使用纳米拓扑结构装置导致引流LN中的摄取和保留最大。
靶向免疫系统的生物制剂的局部区域淋巴递送可能比SC或IV给药具有更有利的药效学。纳米拓扑结构可能为抗TNF药物的递送提供一种更有效的方法,以逆转淋巴功能障碍并减轻与RA发作相关的肿胀。